You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The firms are developing a kit-based CDx to detect NTRK gene fusions, including NTRK1, NTRK2 and NTRK3, for Bayer's Vitrakvi cancer treatment.
The drugmaker will cover the cost of testing for up to 500 patients in the US with MSI-high colorectal cancer or RAI-refractory differentiated thyroid cancer.
Under the deal, the companies aim to develop a companion diagnostic for Bayer's solid tumor drug larotrectinib for the Chinese market.
An IASLC survey showed that molecular testing is not performed in line with expert guidelines, which means only a minority of lung cancer patients are benefitting from precision oncology.
The companies will work together first to develop a companion diagnostic for Bayer's TRK inhibitor larotrectinib, with opportunities to expand to other drugs and drug candidates thereafter.
The effort, called FAIRplus, commenced earlier this year with a budget of €8.2 million, funded by the Innovative Medicine Initiative.
The overlapping development programs for first-generation larotrectinib and second-generation LOXO-195 signal narrowing drug development timelines in the era of precision oncology.
In order to be eligible for the drug, patients must have NTRK fusions, which may be determined via various tests including NGS and FISH.
In development for several years, PORTIN is now being deployed as a single point of reference for all genotype and phenotype data at Bayer's research sites.
The partners have been working together since 2013 to use cancer and cardiovascular genomics for drug discovery.
Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.
Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.
The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.
This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.